Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Amplia Therapeutics Partners with Eli Lilly in FAK-KRAS Combination Lung Cancer Trial
Amplia Therapeutics partners with Eli Lilly for a Phase 1b/2b NSCLC trial of narmafotinib plus olomorasib, targeting KRAS G12C resistance and expanding market.
Latest Stories — SECTOR DESK
Paradigm Biopharmaceuticals Completes Phase 3 Enrolment Ahead of September Interim Analysis
Paradigm Biopharmaceuticals completes Phase 3 PARA_OA_012 enrolment for Zilosul in knee OA; interim analysis in Aug 2026; top-line results Q1 2027.
Adherium Reports Fourth Straight Quarter of Record RPM Revenue
Adherium logs fourth straight quarter of record RPM revenue, $479k to June, with 3,831 activated patients and a 68,000-patient pipeline as growth accelerates.
Imricor Launches US Operations with Cardiac Imaging System at Rady Children’s Hospital in San Diego
Imricor launches US ops with NorthStar MRI-guided cardiac mapping at Rady Children's after FDA paediatric clearance, enabling radiation-free procedures.
Adherium Outlines Commercial Progress and Value-Based Care Strategy
Adherium shifts to recurring respiratory care as RPM revenue surges 9.4x; 5,300 devices shipped, 2,600+ active patients, US$55/mo, targeting 10,000 by year-end.
Resonance Health Improves Cash Position as Clinical Trial Pipeline Expands
Resonance Health boosts FY26 cash to net $2.3m, receipts $14.3m; pipeline over $12m as MRI liver fibrosis trial recruitment completes.
Clinuvel Looking to Access Greater Market Share with Corporate Restructure and US Relocation
Clinuvel relocates HQ to US, trims up to 20% staff, refocuses on US pipeline; Nasdaq listing aims to boost US investor access and partnerships.
Proteomics International Appoints Healius Exclusive Australian Distributor for Promarker Blood Tests
Proteomics inks exclusive Australian distributor deal with Healius for Promarker blood tests, enabling nationwide rollout by 2027; revenue not yet estimable.
Radiopharm Theranostics Reports Positive Results from RAD204 and RAD101 Trials
Radiopharm Theranostics reports durable partial response for RAD204 in Phase 1; RAD101 Phase 2b brain mets shows 93% MRI-PET concordance, 86% sensitivity.
Lumos Diagnostics Expands FebriDx Rollout Across Priority US Urgent Care Accounts
Lumos Diagnostics expands FebriDx rollout to 430 US urgent care sites across top accounts, targeting 2.6 million ARI visits annually—rapid expansion under way.
Optiscan Imaging Advances Head and Neck Cancer Study Ahead of Schedule
Optiscan Imaging pushes Stage 2 of head and neck cancer live-imaging study ahead of schedule, accelerating clinical validation and potential FDA submissions.
LTR Pharma Executes US Commercialisation Agreement with Shed DTC Platform
LTR Pharma inks US ROXUS deal with Shed; targets 150k units in year one via Mavrox telehealth—fast-acting 10-min onset.